OverviewSuggest Edit

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products.

TypePublic
Founded2001
HQWien, AT
Websitenabriva.com

Latest Updates

Employees (est.) (Jan 2019)110(+25%)
Revenue (FY, 2019)$9.5 M(-1%)
Share Price (Oct 2020)$0.6 (+2%)
Cybersecurity ratingBMore

Key People/Management at Nabriva Therapeutics

Denise Pollard-Knight

Denise Pollard-Knight

Director

Nabriva Therapeutics Office Locations

Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin and Dublin 1
Wien, AT (HQ)
Leberstrasse 20
Dublin, IE
Alexandra House, The Sweepstakes
Dublin 1, IE
25 N Wall Quay, North Wall
King of Prussia, US
1000 Continental Dr #600
Show all (4)

Nabriva Therapeutics Financials and Metrics

Nabriva Therapeutics Revenue

Nabriva Therapeutics's revenue was reported to be $9.48 m in FY, 2019
USD

Revenue (Q1, 2020)

789.0k

Gross profit (Q1, 2020)

781.0k

Gross profit margin (Q1, 2020), %

99%

Net income (Q1, 2020)

(23.3m)

EBIT (Q1, 2020)

(20.2m)

Market capitalization (20-Oct-2020)

84.4m

Closing stock price (20-Oct-2020)

0.6

Cash (30-Jun-2020)

49.7m

EV

42.2m
Nabriva Therapeutics's current market capitalization is $84.4 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

9.7m9.5m

Cost of goods sold

70.0k

Gross profit

9.4m

Gross profit Margin, %

99%
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

7.6m847.0k461.0k1.7m525.0k6.9m789.0k

Cost of goods sold

15.0k8.0k

Gross profit

6.9m781.0k

Gross profit Margin, %

100%99%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

32.8m86.8m102.0m86.0m

Accounts Receivable

2.7m

Prepaid Expenses

1.2m1.6m1.2m1.2m

Inventories

682.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

27.2m20.1m112.2m89.4m75.3m100.3m91.0m58.7m78.1m26.9m49.7m

Accounts Receivable

6.5m3.5m3.2m

Prepaid Expenses

903.0k1.4m1.5m1.0m1.2m1.2m973.0k1.4m1.2m2.9m3.9m

Inventories

162.0k4.2m5.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(54.9m)(74.4m)(114.8m)(82.8m)

Depreciation and Amortization

233.0k432.0k510.0k396.0k

Inventories

(682.0k)

Accounts Payable

(383.0k)2.6m(3.0m)1.3m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(15.2m)(29.8m)(52.1m)(13.3m)(31.1m)(84.0m)(20.2m)(41.9m)(59.7m)(23.3m)(38.7m)

Depreciation and Amortization

76.0k149.0k295.0k133.0k262.0k391.0k125.0k245.0k162.0k103.0k209.0k

Inventories

(162.0k)(3.5m)(4.5m)

Accounts Payable

1.8m5.0m2.6m(1.4m)(2.2m)(1.5m)4.3m(346.0k)(39.0k)(2.5m)(1.9m)
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Nabriva Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Zavante Therapeutics IncJuly 25, 2018$124 m

Nabriva Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Nabriva Therapeutics Online and Social Media Presence

Embed Graph

Nabriva Therapeutics News and Updates

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection

Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities

Nabriva Therapeutics Announces $20 Million Registered Direct Offering

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered int…

Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

NDA resubmission anticipated early in the fourth quarter 2019 NDA resubmission anticipated early in the fourth quarter 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV

NEW YORK, June 17, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc ("Nabriva" or the "Company") (NASDAQ: NBRV) and certain of its officers. The class action, filed in United States District Court, for the Southern...

Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

DUBLIN, Ireland, May 10, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2019 and rec…
Show more

Nabriva Therapeutics Blogs

WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta® (Lefamulin)

WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on

Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe   CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA   European Commission

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference Content Import Wed, 05/27/2020 - 16:01 Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference May 27, 2020 at 4:01 PM EDT This release is a backfill from a N…

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines DUBLIN, Ireland , May 18, 2020 (GLOBE NEWSWIRE) -- Nabriva

Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates

-Cash runway extended into the fourth quarter of 2020 through judicious resource management- - XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via non-dilutive support- -Conference call today at
Show more

Nabriva Therapeutics Frequently Asked Questions

  • When was Nabriva Therapeutics founded?

    Nabriva Therapeutics was founded in 2001.

  • Who are Nabriva Therapeutics key executives?

    Nabriva Therapeutics's key executives are Denise Pollard-Knight.

  • How many employees does Nabriva Therapeutics have?

    Nabriva Therapeutics has 110 employees.

  • What is Nabriva Therapeutics revenue?

    Latest Nabriva Therapeutics annual revenue is $9.5 m.

  • What is Nabriva Therapeutics revenue per employee?

    Latest Nabriva Therapeutics revenue per employee is $86.2 k.

  • Who are Nabriva Therapeutics competitors?

    Competitors of Nabriva Therapeutics include LGC, NovaBay Pharmaceuticals and Chiasma.

  • Where is Nabriva Therapeutics headquarters?

    Nabriva Therapeutics headquarters is located at Leberstrasse 20, Wien.

  • Where are Nabriva Therapeutics offices?

    Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin and Dublin 1.

  • How many offices does Nabriva Therapeutics have?

    Nabriva Therapeutics has 4 offices.